For a reason that I can not figure out there are a small but still significant portion of medical studies that automatically exclude gays from participating without an apparent scientific reason. These studies usually have requirements that the subject be in a “reciprocal relationship with a person of the opposite sex." Sometimes the exclusion of [...]
Understanding and deciding on appropriate treatments for men with advanced prostate cancer can be confusing. All the treatments come with side effects and one never knows what the benefits might be for an individual. Even with good clinical trials, men with advanced prostate cancer still need to navigate a most unclear path. Provenge, ever since [...]
According to recent trials led by The Institute of Cancer Research (ICR) (UK) and The Royal Marsden (UK) combining Zytiga (abiraterone acetate) with the yet FDA unapproved investigational drug MDV3100 could increase the number of men, with advanced prostate cancer, who respond to treatment as well as the length of time they benefit. A new [...]
Xgeva (denosumab), which has already been approved by the Food and Drug Administration (FDA) for the prevention fractures in men with advanced prostate cancer that has already migrated to the bone, has been rejected by the FDA to expand the use of the drug to delay the spread of tumors in men without metastases to [...]
The Prostate Cancer Research Program (PCRP) of the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) has received our fiscal year 2012 (FY12) funding to support research projects in the prevention, detection, diagnosis, and treatment of Prostate Cancer. This is a critical request and it is important that prostate cancer survivors participate in research [...]